AlphAIalphai — Financial news for AI agents
Stock TitanMAY 12 min read$VNRX

CEO pay, board changes and reverse split at VolitionRx (NYSE: VNRX)

VolitionRx Limited filed an amendment to its annual report, providing detailed Part III information on directors, executive officers, governance, and compensation. The filing also clarifies a one-for-twenty reverse stock split effective April 28, 2026, which retroactively adjusts all share data. As of June 30, 2025, non-affiliate common stock had a market value of $72,909,373, and as of April 28, 2026, there were 8,087,955 common shares outstanding. CEO Cameron Reynolds' total 2025 compensation was $638,233.

Original reporting
Stock Titan
Published May 1, 2026, 5:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 5:30 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$VNRX
Neutral
medium confidence
Mentioned
$VNRX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$VNRXNeutralLow
01

Why it matters

The amendments and share adjustments are procedural and unlikely to affect the company's fundamentals or valuation significantly.

02

Market read

The news has limited immediate impact on the company's stock performance but may influence investor confidence in governance practices.

03

What to watch

Market reaction could be influenced by upcoming financial results or strategic announcements not covered in this report.

Timing: Moderate, as the news was published on 2026-05-01 and pertains to recent filings.

Background

VolitionRx Limited is a life sciences company focusing on cancer diagnostics. The recent filing clarifies corporate governance and share structure.

Company-level read

Ticker impact

$VNRXNeutralMedium confidence
Context

The news pertains directly to VolitionRx Limited, providing detailed information on recent corporate actions, executive compensation, and share structure changes.

Expected impact

Minimal short-term price movement expected; potential for slight positive bias due to transparency and governance improvements.

Evidence & confidence

The news is factual and relates to corporate governance, which generally has a limited immediate impact on stock price unless accompanied by significant financial disclosures or strategic shifts.

Market effects

Sector

Potentially positive for the life sciences sector due to increased transparency and governance.

Regional

Limited, as the news is specific to a U.S.-listed company with no broader regional implications.

Global

Negligible, as the news does not indicate any global market shifts or macroeconomic impacts.

Counterpoint

What could challenge this read

Some investors might interpret the reverse split and executive compensation details as potential red flags indicating management entrenchment or share price manipulation.

Key entities

  • Person
    Cameron Reynolds

    CEO of VolitionRx Limited, with a total compensation of $638,233 in 2025.

  • Company
    VolitionRx Limited

    A life sciences company specializing in cancer diagnostics.

Read at source← All news

Related articles

AUG 8
$NVDAMed

Nvidia to Invest Up to $3 Billion in Blackstone

The Information reported Nvidia plans to invest up to $3 billion in Lancium, a Blackstone-backed power and data center infrastructure developer tied to the Stargate AI initiative. Nvidia would initially put in $2 billion for a 20% stake, with up to $1 billion more contingent on performance thresholds. No company comment was provided.

econotimes.com4 min
AUG 8
$NVDAMed

Nvidia to invest up to US$3 billion in Stargate data centre developer Lancium: The Information

Nvidia plans to invest up to $3 billion in Lancium, the developer of the Stargate data center campus in Texas, The Information reported. Nvidia would invest $2 billion for about a 20% stake, with an additional $1 billion possible based on grid hookup thresholds. Lancium’s land and power portfolio has an enterprise value near $10 billion, and it may explore an IPO in 2027.

businesstimes.com.sg4 min
AUG 8
$USARMed

Is USA Rare Earth (USAR) Overvalued On Its DOE Funding And Tokenization Buzz?

Simply Wall St says USA Rare Earth (USAR) shares have rebounded after being selected by the U.S. Department of Energy for up to $19.3M in federal funding, pending final negotiations, for a pilot-scale rare earth separations project. The article cites mixed valuation views, with a “fair value” of $0.33 versus a DCF estimate of $83.09, and notes recent price returns.

simplywall.st6 min
AUG 8
$000660.KSMed

SK Hynix mulling options for US$3 bil Chongqing plant — Bloomberg

Bloomberg reports SK Hynix is exploring options for its Chongqing, China semiconductor packaging and testing plant, including possibly bringing in an investor. A potential stake sale could value the facility at about US$3 billion, according to people familiar. Separately, SK Hynix plans a 54 trillion won (US$38 billion) South Korea expansion for DRAM and NAND, citing AI-driven demand.

theedgemalaysia.com4 min
AUG 8
$OESXMed

Orion Energy Targets $95M-$97M Revenue After Margin Gains at Annual Meeting

Orion Energy Systems (NASDAQ:OESX) reported FY2026 revenue targets of $95M to $97M and expects positive adjusted EBITDA for the year, after margin gains at its annual meeting. LED lighting revenue rose to $55.9M from $47.7M, with gross margin up to 33.8%. EV charging revenue fell to $14.4M from $16.8M, while maintenance revenue rose to $16.0M.

yahoo.com4 min